Inter partes review (IPR) proceedings before the Patent Trial and Appeal Board (PTAB) of the USPTO have been popular since their inception in 2012, and petitions are increasingly being filed against biologic drug patents. Fitzpatrick Cella’s award-winning intellectual property attorneys provide you with unique insights and the latest statistics on biologic drug IPRs and the lessons to be learned from recent institution and final written decisions.
Corinne Atton, Whitney Meier, and Robert Schwartz will discuss:
This webinar is perfect for life sciences professionals interested in understanding how IPRs are being used to challenge biologic drug patents.
Join us on Thursday, February 22, 2018 at noon EST for this complimentary webinar.
Corinne E. Atton practices complex patent litigation with a focus on pharmaceuticals, biologics, biotechnology, and medical devices. Corinne has worked on cases concerning, among other things, DNA sequencing technologies, recombinant polypeptides, enzyme inhibitors, iron chelators, and anti-diabetic drugs. She also has experience of patent due diligence associated with high profile acquisitions. Corinne has represented clients at district court and appellate levels, and in inter partes review proceedings before the U.S. Patent Trial and Appeal Board. Corinne received a B.Sc. (Hons) in Human Genetics from University College London (UCL), before training as a barrister in England, where she was involved in high value patent litigations, trademark litigations, and commercial litigations and arbitrations. Corinne regularly writes articles on patent-related issues, particularly concerning biologics, and inter partes review proceedings. Corinne manages Fitzpatrick’s www.BiologicsHQ.com - a website that provides statistical analyses and timely commentary concerning U.S. patent proceedings relating to FDA-approved biologic drugs.
Whitney Meier’s practice focuses on complex patent litigation with an emphasis on chemistry, biotechnology, and pharmaceuticals. She has litigated cases concerning chemotherapies, transgenic mice, antibodies, cough suppressants, and treatments for osteoporosis. Whitney’s experience includes foreign patent opposition proceedings, inter partes reviews, and opinion work. Her practice also includes many aspects of trademark law, including clearing and prosecuting U.S. and foreign trademarks. Whitney received a B.S. degree in biochemistry from the University of Virginia.
Robert S. Schwartz, Ph.D. focuses his practice on biotechnology and pharmaceutical patent litigation and USPTO contested cases. His primary focus is in the areas of biotechnology, including transgenic mice, antibodies, siRNA, nucleotide prodrugs, enzyme inhibitors, cell growth factors, receptor antagonists, DNA sequencing technology and vaccines. Bob received his Ph.D. in biochemistry from the University of California at Berkeley. Prior to joining Fitzpatrick he was an Associate Professor of Medicine at the Albert Einstein College of Medicine, Bronx, NY where he was a Principal Investigator of grant-funded biomedical research. Bob has published over 40 scientific articles and book chapters in peer-reviewed journals, as well as numerous legal articles relating to subject matter patentability, biologics and biosimilars. Bob is chair of the firm's Biotechnology and Biologics Industry Group and is a frequent speaker at conferences on topics relating to biologics and biosimilars.